Výsledky vyhledávání - "Elizabeth Molsen"

Akademický článek

Validation of Electronic Systems to Collect Patient-Reported Outcome (PRO) Data - Recommendations for Clinical Trial Teams: Report of the ISPOR ePRO Systems Validation Good Research Practices Task Force

Autor: Arthur Zbrozek, Joy Hebert, Gregory Gogates, Rod Thorell, Christopher Dell, Elizabeth Molsen, Gretchen Craig, Kenneth Grice, Scottie Kern, Sheldon Hines, A. V. Pavlysh, A. A. Toporov, E. V. Verbitskaya, A. S. Kolbin

Publikováno v: Качественная клиническая практика, Vol 0, Iss 2, Pp 3-18 (2018)

Externí odkaz: https://doaj.org/article/f4f4ff16725149c7a6da73a128506c96

Zobrazit plný text záznamu

Akademický článek

Multinational Trials - Recommendations on the Translations Required, Approaches to Using the Same Language in Different Countries, and the Approaches to Support Pooling the Data: The ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Good Research Practices Task Force Report

Autor: Diane Wild, Sonya Eremenco, Isabelle Mear, Mona Martin, Caroline Houchin, Mary Gawlicki, Asha Hareendran, Ingela Wiklund, Lee Yee Chong, Robyn Von Maltzahn, Lawrence Cohen, Elizabeth Molsen, A. V. Pavlysh, E. V. Verbitskaya

Publikováno v: Качественная клиническая практика, Vol 0, Iss 2, Pp 29-43 (2018)

Externí odkaz: https://doaj.org/article/2a5b50964c6f471183ac18fd59e0b0b7

Zobrazit plný text záznamu

Is IQWiG's 15% Threshold Universally Applicable in Assessing the Clinical Relevance of Patient-Reported Outcomes Changes? An ISPOR Special Interest Group Report

Autor: Michael Schlichting, Michael Hennig, Katja Rudell, Lori McLeod, Bryan Bennett, James Shaw, Lynda Doward, Elizabeth Molsen-David, Olivier Chassany

Publikováno v: Value in Health. 25:1463-1468

This article discusses a recent methodological change to assess the additional benefit of drug intervention by the German Federal Joint Committee (Gemeinsamer Bundesausschuss), a key stakeholder in EUnetHTA21 (European Network for Health Technology A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a068287b6dc6f337e3f7b6dd74555045
https://doi.org/10.1016/j.jval.2022.07.010

Zobrazit plný text záznamu

Medical Nutrition Terminology and Regulations in the United States and Europe—A Scoping Review: Report of the ISPOR Nutrition Economics Special Interest Group

Autor: Sheri Volger, Mickaël Hiligsmann, Clarissa Cooblall, Karen Freijer, Irene Lenoir-Wijnkoop, Silvia M. A. A. Evers, Elizabeth Molsen-David, Aurelie Danel, János G Pitter

Publikováno v: Value in Health. 22:1-12

Background The term medical nutrition (MN) refers to nutritional products used under medical supervision to manage disease- or condition-related dietary needs. Standardized MN definitions, aligned with regulatory definitions, are needed to facilitate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::765eac57e4d794475d0d3725ceac3623
https://doi.org/10.1016/j.jval.2018.07.879

Zobrazit plný text záznamu

Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions—Report of the ISPOR Stated Preference Research Special Interest Group

Autor: Janine van Til, Axel Muehlbacher, Jan Ostermann, Thomas G. Poder, Y. Christy Choi, Natalia Hawken, EM Oehrlein, Alejandra Duenas, Elizabeth Molsen-David, Mickaël Hiligsmann, Kimberley Hockley, Wolfgang Greiner, Frank Xiaoqing Liu, Jiat Ling Poon, Ilya Ivlev, Kara Haas, Christine Juhnke, Kevin Marsh

Publikováno v: Value in Health
Value in Health, Elsevier, 2020, 23 (7), pp.831-841. ⟨10.1016/j.jval.2019.11.009⟩
Value in health, 23(7), 831-841. Elsevier

OBJECTIVE: This study examines European decision makers' consideration and use of quantitative preference data.; METHODS: The study reviewed quantitative preference data usage in 31 European countries to support marketing authorization, reimbursement

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::506d08df7ebed89ef28473f90022add0
https://hal.archives-ouvertes.fr/hal-02972372

Zobrazit plný text záznamu

Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group

Autor: Mondher Toumi, Zoltán Kaló, Elizabeth Molsen, Sandra Nestler-Parr, Christopher M. Blanchette, William K. Redekop, Thomas Morel, Steven Simoens, CL Pashos, D Korchagina, Ruediger Gatermann

Publikováno v: Value in Health, 21(5), 493-500. Elsevier Ltd.

Background Successful development of new treatments for rare diseases (RDs) and their sustainable patient access require overcoming a series of challenges related to research and health technology assessment (HTA). These impediments, which may be uni

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2785824d5baee02fb95dd7b1fba08692
https://hdl.handle.net/1765/105771

Zobrazit plný text záznamu

Rare Disease Terminology and Definitions—A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group

Autor: Theresa Tesoro, Sandra Nestler-Parr, Zeba M. Khan, Dyfrig A. Hughes, Robert Babela, Trevor Richter, Elizabeth Molsen

Publikováno v: Value in Health. 18(6):906-914

Background At present, there is no universal definition of rare disease. Objective To provide an overview of rare disease definitions currently used globally. Methods We systematically searched for definitions related to rare disease from organizatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::027c815a6569a8de6bbea8d50ac3b135

Zobrazit plný text záznamu

ISPOR Code of Ethics 2017 (4th Edition)

Autor: Elizabeth Molsen-David, Michael Drummond, Francis B. Palumbo, William D. Marder, Richard J. Willke, Louise Parmenter, Asrul Akmal Shafie, Anita Ho, Jessica Santos, Louise Binder, Gurmit Sandhu, David M. Thompson

Publikováno v: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 20(10)

As the leading health economics and outcomes research (HEOR) professional society, ISPOR has a responsibility to establish a uniform, harmonized international code for ethical conduct. ISPOR has updated its 2008 Code of Ethics to reflect the current

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72ec76568972f349abd5cab5c2339a97
https://pubmed.ncbi.nlm.nih.gov/29241882

Zobrazit plný text záznamu

PP177 Health Preference Research In Europe: A Review Of Its Use

Autor: Kara Haas, Jan Ostermann, Mickaël Hiligsmann, Yookyung Christy Choi, Wolfgang Greiner, Axel C. Mühlbacher, Natalia Hawken, Thomas G. Poder, Elizabeth Molsen-David, Kimberley Hockley, Alejandra Duenas, Christin Juhnke, EM Oehrlein, Janine Astrid van Til, Frank Xiaoqing Liu, Kevin Marsh, Ilya Ivlev

Publikováno v: International Journal of Technology Assessment in Health Care. 35:70-70

IntroductionHealth Technology Assessment (HTA) and regulatory decisions involve value judgements. As patient groups, industry, and regulatory agencies conduct more preference studies to quantify these judgements, a better understanding of the methods

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::14be7bf262b8da6d3760ce7d4e874aeb
https://doi.org/10.1017/s0266462319002691

Zobrazit plný text záznamu

Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force

Autor: Maria Isaac, Spiros Vamvakas, Ashley F. Slagle, Elizabeth Molsen, Stefan J. Cano, Patrick Marquis, Marc K. Walton, John H. Powers, Jeremy Hobart, Laurie B. Burke, Donald L. Patrick

Publikováno v: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 20(1)

A clinician-reported outcome (ClinRO) assessment is a type of clinical outcome assessment (COA). ClinRO assessments, like all COAs (patient-reported, observer-reported, or performance outcome assessments), are used to 1) measure patients' health stat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::013503da19ed9402d0a1f9660bae83de
https://pubmed.ncbi.nlm.nih.gov/28212956

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání